Skip to main content
Terug
BHVN logo

Biohaven Ltd.

Datakwaliteit: 100%
Oversold
BHVN
NYSE Healthcare Biotechnology
€ 8,39
▼ € 0,35 (-4,00%)
Marktkapitalisatie: 888,21M
Dagbereik
€ 8,28 € 8,70
52-Weeksbereik
€ 7,48 € 31,18
Volume
2.285.970
50D / 200D Gem.
€ 11,31 / € 13,04
Vorige Slotkoers
€ 8,74

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -1,2 0,3
P/B 17,1 2,9
ROE % -310,8 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 5,4 0,2

Koersdoel Analisten

Hold
€ 21,29 +153.8%
Low: € 10,00 High: € 42,00
Forward WPA
-€ 2,98
Omzet Sch.
2,5 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,26
€ 0,05 – € 0,72
780 M 4
FY2029 -€ 1,47
-€ 4,13 – -€ 0,30
330 M 4
FY2028 -€ 2,25
-€ 4,07 – -€ 0,10
110 M 11

Belangrijkste Punten

Debt/Equity of 5,36 — high leverage
Negative free cash flow of -610,15M
PEG of 0,06 suggests growth is underpriced

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-310,75%
ROIC-168,93%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
5,36
Current Ratio3,18
Interest Coverage0,00

Waardering

P/E Ratio
-1,20
P/B Ratio17,06
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -738,82M
ROE -310,75% ROA -163,66%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -610,15M
ROIC -168,93% FCF Growth (3Y) N/A
Safety
Debt / Equity 5,36 Current Ratio 3,18
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -1,20 P/B Ratio 17,06
P/S Ratio N/A PEG Ratio 0,06
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 888,21M Enterprise Value 937,11M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -738,82M -846,42M -408,17M -570,28M -213,80M
EPS (Diluted) -6,86 -9,28 -5,73 -12,75 -5,97
Gross Profit -4,14M 0,0 0,0 0,0 0,0
Operating Income -745,38M -885,11M -436,05M -567,93M -218,90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 451,45M 615,11M 513,21M 661,78M 142,06M
Total Liabilities 399,38M 191,67M 85,24M 123,01M 47,37M
Shareholders' Equity 52,07M 423,44M 427,98M 538,77M 34,69M
Total Debt 278,86M 36,58M 30,88M 33,60M 3,24M
Cash & Equivalents 229,96M 99,13M 248,40M 204,88M 76,06M
Current Assets 368,33M 538,47M 442,45M 586,97M 94,82M
Current Liabilities 115,93M 154,23M 55,42M 90,02M 41,94M